Howdy GW, greetings from OZ......

Late-Breaking Data Submission Guidelines

The ASCO late-breaking data policy allows for the submission of late-breaking data only for:

• Randomized phase II and III trials for which no preliminary data are available at the time of the abstract submission deadline (January 28, 2025);

OR

• Original research studies that highlight novel and high-impact research with practice-changing implications

The initial abstract must be submitted by the January 28, 2025 deadline as a placeholder (shell) abstract submission. During submission, you will be required to enter all authors and their disclosures, the Background and Methods sections, provide the primary clinical endpoint for analysis, type of analysis, date of planned analysis, and planned statistical methods.

If I'm reading this right if Immutep didn't submit an abstract application by 28th of January, which I have not seen any evidence they have,
there is no avenue to apply for a late breaking abstract presentation..
I've had a few looks at this scenario over the past couple of weeks from different directions and come
to the same conclusion each time...
Whilst immutep will attend asco I don't think they are doing any presentations...Off coarse this doesn't mean some of our
partners won't be, I haven't looked that far, so am in the dark there..